This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Treatment and prognosis

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

The treatment options for a patient with the cholesterol emboli syndrome are limited:

  • multiple treatment regimens have been generally unsuccessful in altering the course of the disease process
    • most significant impact on the disease can be made by its prevention
    • thrombolytic and anticoagulant treatments are not indicated and only supportive care for such symptoms as hypertension, ulceration, and gangrene is advocated (1)
  • amputation of affected lower limb may be necessary; an end-diastolic pneumatic boot has been used as an alternative to amputation (2)

Prognosis depends on the extent of the systemic disease and a high rate of mortality (75-80%) is recorded due to multifactorial, cardiac, and renal aetiologies

Notes:

  • statins may help to stabilise atheromatous plaques
  • steroids have previously been used to attempt to reduce the inflammatory component

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.